Health Care & Life Sciences » Biotechnology | Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S | Income Statement

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
38,148.00
123,395.00
14,150.00
61,879.80
198,946.60
249,514.90
Cost of Goods Sold (COGS) incl. D&A
-
4,240.00
16,613.00
21,719.20
35,658.30
51,243.60
Gross Income
-
119,155.00
2,463.00
40,160.60
163,288.30
198,271.30
SG&A Expense
171,725.00
177,759.00
194,637.00
234,455.40
218,414.60
235,141.90
EBIT
136,135.00
58,604.00
197,100.00
194,294.70
55,126.30
36,870.60
Non Operating Income/Expense
5,630.00
20,553.00
14,445.00
5,000.70
1,226.60
372.80
Interest Expense
39.00
-
-
4,630.60
15,095.60
39,827.40
Pretax Income
140,561.00
37,701.00
182,514.00
193,924.60
68,909.50
74,878.50
Income Tax
1,250.00
1,382.00
6,408.00
125,711.40
5,981.50
41,488.90
Consolidated Net Income
139,311.00
36,319.00
176,106.00
68,213.20
62,928.00
33,389.50
Net Income
139,311.00
36,319.00
176,106.00
68,213.20
62,928.00
33,389.50
Net Income After Extraordinaries
139,311.00
36,319.00
176,106.00
68,213.20
62,928.00
33,389.50
Net Income Available to Common
139,311.00
36,319.00
176,106.00
68,213.20
62,928.00
33,389.50
EPS (Basic)
0.08
0.02
0.11
0.07
0.07
0.02
Basic Shares Outstanding
1,660,353.20
1,662,266.60
1,663,334.20
1,688,679.40
1,708,325.60
1,713,188.80
EPS (Diluted)
0.08
0.02
0.11
0.04
0.04
0.02
Diluted Shares Outstanding
1,660,353.20
1,662,266.60
1,663,334.20
1,688,679.40
1,708,325.60
1,713,188.80
EBITDA
134,820.00
57,611.00
195,626.00
192,894.80
53,774.30
35,651.30
Other Operating Expense
1,243.00
-
-
-
-
-
Non-Operating Interest Income
1,243.00
350.00
141.00
-
85.70
2,192.30

About Veloxis Pharmaceuticals A/S

View Profile
Address
Amerika Plads 37
Copenhagen CR 2100
Denmark
Employees -
Website http://www.veloxis.com
Updated 07/08/2019
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.